Please login to the form below

Not currently logged in

Novartis extends WHO leprosy collaboration

Novartis has announced it is to extend its collaboration with the World Health Organization to help end leprosy

Novartis has announced it has signed a new Memorandum of Understanding (MoU) to extend its collaboration with the World Health Organization (WHO) to end leprosy.

The Switzerland-based company said it will continue to provide free multidrug therapy (MDT) medicines worth $26m to the agency, with estimates that 1.1 million leprosy patients will be treated during the five-year period from January 2011 to December 2015.

Handling costs will also be covered by Novartis.

Speaking on the agreement, Joe Jimenez, CEO of Novartis, said: "We are committed to ensuring that patients receive the medications they need and we intend to contribute to this programme until the final elimination of this debilitating disease."

Novartis has worked with the WHO for 10 years, donating treatments worth a total of $60m to help around five million patients.

The company is also continuing its commitment to educate people about the disease through the Novartis Foundation for Sustainable Development (NFSD).

NFSD's work includes collaborating with the Novartis Comprehensive Leprosy Care Association (NCLCA) in India to offer health education to leprosy patients, as well as providing physical aids such as prefabricated hand and foot splints.

India is one of several countries containing areas where leprosy is still prevalent, with others including Angola, Brazil, Madagascar and Nepal. The WHO describe information campaigns about leprosy in these high-risk areas as 'crucial' in encouraging people to come forward and receive treatment.

Cases of leprosy have decreased 95 per cent over the past 20 years. It is now estimated that there are fewer than 250,000 cases of the disease globally.

12th October 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...